Primary Site >> Colorectal Cancer
Gene >> IGF1R
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Type I insulin-like growth factor receptor expression on colorectal adenocarcinoma cell lines is decreased in response to the chemopreventive agent N-acetyl-l-cysteine. PMID: 12485928 |
Ref: [Insulin-like growth factor receptor, hepatocyte-derived growth factor receptor and telomerase expression in ulcerative colitis]. PMID: 17066600 |
Ref: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. PMID: 18577988 Ref: Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 re PMID: 18636198 Ref: Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. PMID: 18829558 Ref: Elevated insulin-like growth factor 1 receptor, hepatocyte growth factor receptor and telomerase protein expression in mild ulcerative colitis. PMID: 18938767 Ref: Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). PMID: 19343143 Ref: Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling. PMID: 19763245 |
Ref: Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. PMID: 19608011 Ref: Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications. PMID: 19773552 Ref: Curcumin synergizes with resveratrol to inhibit colon cancer. PMID: 19838927 |
Ref: Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. PMID: 20459642 Ref: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. PMID: 20504360 Ref: Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. PMID: 20530704 Ref: Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. PMID: 20718704 Ref: ChIP-seq and Functional Analysis of the SOX2 Gene in Colorectal Cancers. PMID: 20726776 Ref: ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. PMID: 20726797 Ref: The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. PMID: 20920993 Ref: Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. PMID: 20935157 Ref: Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. PMID: 20978316 Ref: Thrombopoietin receptor levels in tumor cell lines and primary tumors. PMID: 21318160 |
Ref: Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. PMID: 21340604 Ref: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? PMID: 21729677 Ref: miRNA Alterations Modify Kinase Activation In The IGF-1 Pathway And Correlate With Colorectal Cancer Stage And Progression In Patients. PMID: 21980324 |
Ref: Monosodium glutamate-induced diabetic mice are susceptible to azoxymethane-induced colon tumorigenesis. PMID: 22223845 Ref: Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. PMID: 22312273 Ref: miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. PMID: 22373578 Ref: The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PMID: 22558377 |
Ref: A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. PMID: 23485230 Ref: Curcumin affects proprotein convertase activity: elucidation of the molecular and subcellular mechanism. PMID: 23583304 Ref: A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome. PMID: 23604467 Ref: Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by (1)(7)(7)Lu-labeled siRNA targeting IGF-1R. PMID: 23618769 Ref: The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma. PMID: 23801064 Ref: Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. PMID: 23806981 Ref: Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. PMID: 24045180 Ref: The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. PMID: 24050852 Ref: Differential PKA activation and AKAP association determines cell fate in cancer cells. PMID: 24083380 Ref: Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). PMID: 24107449 Ref: Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer. PMID: 24282367 Ref: Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer. PMID: 27340651 |
Ref: In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. PMID: 24173770 Ref: Racial differences in the association of insulin-like growth factor pathway and colorectal adenoma risk. PMID: 24194259 Ref: Calcium deficiency-induced and TRP channel-regulated IGF1R-PI3K-Akt signaling regulates abnormal epithelial cell proliferation. PMID: 24336047 Ref: Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. PMID: 24412052 Ref: Ezrin expression and cell survival regulation in colorectal cancer. PMID: 24462708 Ref: IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. PMID: 24492468 Ref: MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. PMID: 24533778 Ref: Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. PMID: 24581231 Ref: Polymorphisms in the insulin-like growth factor axis are associated with gastrointestinal cancer. PMID: 24608110 Ref: mRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes. PMID: 24751329 Ref: Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway. PMID: 24818842 Ref: Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer. PMID: 24942287 Ref: Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases. PMID: 24961901 Ref: Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PMID: 25090459 Ref: Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development. PMID: 25189651 Ref: MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. PMID: 25287248 Ref: MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PMID: 25474488 |
Ref: Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. PMID: 24816908 Ref: A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. PMID: 25212606 Ref: A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. PMID: 25335932 Ref: Insulin-Like Growth Factor-1 Modulates Polycomb Cbx8 Expression and Inhibits Colon Cancer Cell Apoptosis. PMID: 25398592 Ref: Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo. PMID: 25895029 Ref: Knockdown of type I insulin-like growth factor receptor inhibits human colorectal cancer cell growth and downstream PI3K/Akt, WNT/beta-catenin signal pathways. PMID: 26211576 Ref: Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PMID: 26258407 Ref: BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis. PMID: 26438154 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 |
Ref: Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. PMID: 26831715 Ref: Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation. PMID: 26861122 Ref: Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. PMID: 27099521 Ref: Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer Progression. PMID: 27243824 Ref: Calycosin induces apoptosis in colorectal cancer cells, through modulating the ERbeta/MiR-95 and IGF-1R, PI3K/Akt signaling pathways. PMID: 27393650 Ref: IGF1R and c-met as therapeutic targets for colorectal cancer. PMID: 27470393 Ref: miR-448 suppresses proliferation and invasion by regulating IGF1R in colorectal cancer cells. PMID: 27508021 Ref: Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. PMID: 27569653 Ref: Does IGF-1 play a role in the biology of endometrial cancer? PMID: 27629137 Ref: Genomic characterization of liver metastases from colorectal cancer patients. PMID: 27662660 Ref: The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells. PMID: 27813496 |
Ref: MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. PMID: 27840990 Ref: Downregulation of microRNA-100/microRNA-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion. PMID: 28032929 Ref: Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. PMID: 28138221 Ref: TGFbeta/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells. PMID: 28414818 Ref: Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy. PMID: 28427155 Ref: Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7. PMID: 28435295 Ref: Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. PMID: 28534511 Ref: The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy. PMID: 28729397 Ref: The Axis of CXCR4/SDF-1 Plays a Role in Colon Cancer Cell Adhesion Through Regulation of the AKT and IGF1R Signalling Pathways. PMID: 28739729 Ref: Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. PMID: 28751539 Ref: Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death. PMID: 28823963 Ref: MicroRNA-30a Inhibits Colorectal Cancer Metastasis Through Down-Regulation of Type I Insulin-Like Growth Factor Receptor. PMID: 28932920 Ref: Multiple Gene-Environment Interactions on the Angiogenesis Gene-Pathway Impact Rectal Cancer Risk and Survival. PMID: 28956832 Ref: IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer. PMID: 29123265 Ref: Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. PMID: 29167573 Ref: Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer. PMID: 29290648 |
Ref: Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation. PMID: 29217764 Ref: CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. PMID: 29549306 Ref: Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. PMID: 29559746 Ref: Fisetin mediated apoptotic cell death in parental and Oxaliplatin/irinotecan resistant colorectal cancer cells in vitro and in vivo. PMID: 29574877 Ref: TGFbeta and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells. PMID: 29599290 Ref: IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. PMID: 29886785 Ref: NUDCD1 promotes metastasis through inducing EMT and inhibiting apoptosis in colorectal cancer. PMID: 29888104 Ref: beta-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer. PMID: 29895971 Ref: MiR-185 enhances radiosensitivity of colorectal cancer cells by targeting IGF1R and IGF2. PMID: 29990869 |